Comparative Pharmacology
Head-to-head clinical analysis: FABRAZYME versus PALYNZIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABRAZYME versus PALYNZIQ.
FABRAZYME vs PALYNZIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
2.4 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy